![Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy](http://prnewswire.vietreader.com/thumb/190x300/2024-01/positive-xanamem-human-pet-study-published-in-the-journal-of-alzheimers-disease-demonstrating-robust-cns1-target-enzyme-occupancy-1.jpg)
Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy
The study confirms that Xanamem is a brain-penetrant inhibitor of the tissue cortisol synthesis enzyme, 11 β -HSD1, with high levels of target occupancy at doses as low as 5 mg SYDNEY, Jan. 24, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX:...